<DOC>
	<DOC>NCT00937911</DOC>
	<brief_summary>The study objective is to evaluate the efficacy and safety of oral YM150 for prevention of venous thromboembolism in subjects undergoing hip fracture surgery or surgery in the lower extremities.</brief_summary>
	<brief_title>Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Darexaban</mesh_term>
	<criteria>Subjects undergoing hip fracture surgery or patients undergoing surgery in the lower extremities other than hip fracture surgery Written informed consent obtained before screening Subject has history of deep vein thrombosis and/or pulmonary embolism Subject has a hemorrhagic disorder and/or coagulation disorder Subject has had clinically important bleeding occurred within 90 days prior to the screening visit Subject has an acute bacterial endocarditis Subject has uncontrolled severe or moderate hypertension, retinopacy, myocardial infarction or stroke Subject is receiving anticoagulants/antiplatelet agents Subject has a body weight less than 40 kg</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>YM150</keyword>
	<keyword>Bleeding</keyword>
	<keyword>Anticoagulant</keyword>
	<keyword>Venous thromboembolism</keyword>
	<keyword>FXa inhibitor</keyword>
</DOC>